Browsing: Health
The World Health Organization has urged a wider Ebola response in the Democratic Republic of the Congo as transmission continues across several provinces. Congo had recorded 6,250 confirmed cases and 3,039 deaths by Sept. 1, according to the latest government figures. The outbreak has affected 60 health zones in six provinces. Authorities have also recorded 1,439 recoveries, while the case fatality rate stands at 48.6%.
Health Minister Roger Kamba confirmed that the government initiated the immunization campaign utilizing doses of the Ervebo vaccine to safeguard frontline personnel operating across impacted eastern provinces.
The European Commission has expanded its Ebola response with a €2.1 million purchase of PCR tests for the Bundibugyo virus outbreak. Shipments are due to start in August as health teams confront a large outbreak centered in the Democratic Republic of the Congo and affecting parts of the wider region. The World Health Organization will receive the tests through its Hub for Global Health Emergencies Logistics in Dubai for distribution to locations supporting the Ebola response. PCR testing allows laboratories to confirm infections and support surveillance around known cases, guiding patient care, isolation, and contact tracing.
Australian researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have identified a novel molecular switch that drives the spread of aggressive tumors. Published in EMBO Molecular Medicine, the breakthrough study reveals that Australian researchers uncover a promising new way to tackle triple-negative breast cancer by restoring a critical regulatory molecule known as miR-342. The discovery opens new avenues to prevent life-threatening secondary cancers in organs such as the lungs and bones. Triple-negative breast cancer accounts for 10% to 15% of Australia’s approximately 21,000 annual breast cancer diagnoses but causes a disproportionate number of deaths. Lead investigators demonstrated that when miR-342 levels fall, a cancer-driving pathway called E2F becomes overactive, allowing dormant cancer cells to spread throughout the body and form dangerous secondary tumors.
The Democratic Republic of the Congo will receive 70,000 Ervebo Ebola vaccine doses as the Bundibugyo outbreak expands. Congolese authorities reported 5,208 confirmed cases and 2,476 deaths as of Aug. 18. The outbreak now affects 56 health zones across six provinces in the east and northeast. Authorities also listed 1,115 recoveries, while 730 patients remained in isolation or hospital care.
WHO incident manager Thierno Baldé said the three-month timeline depends on securing the resources required for the response. The agency has received about $69.3 million of the $115 million it says it needs, or roughly 60%. Teams added more than 400 treatment beds during the past two weeks. They also deployed 100 additional epidemiologists and more than 500 community health workers for surveillance and contact tracing. The response requires vehicles, ambulances, medical supplies and personnel across a growing affected area. Transmission has reached Bas-Uélé, making it the sixth affected province. As of Aug. 12, Ituri accounted for 85% of confirmed cases and 79% of reported deaths nationwide. Officials said 70% to 80% of new cases had no known link to existing patients. Health teams are expanding surveillance to identify cases faster and transfer patients into treatment centers. Bas-Uélé’s first confirmed case had traveled from Haut-Uélé before symptoms began on Aug. 4.
The Democratic Republic of the Congo recorded 26,064,143 malaria cases in 2025. The country also reported 29,938 deaths linked to the disease during the year. Guy Esebe Dembo, deputy director of the National Malaria Control Programme, announced the figures during a campaign launch in Ituri province. Dembo said malaria remains the country’s main public health challenge. The new totals confirm a heavy disease burden across one of Africa’s most malaria-affected countries.
DR Congo’s Ebola outbreak has killed 1,916 people and produced 4,209 confirmed cases, according to official data through Aug. 7. Ituri remains the center of the epidemic, with 3,636 confirmed cases and 1,551 deaths. Health teams continue to review and harmonize case and mortality figures as surveillance records are updated. The virus can cause fever, weakness, body pain, vomiting and other serious symptoms. The response covers communities facing insecurity and high population movement in parts of eastern Congo. No licensed vaccine or specifically approved treatment is currently available for Bundibugyo virus.
The comprehensive epidemiological investigation examined underlying causes of death to determine how elevated body mass index contributes to chronic health conditions. Research findings identified cardiovascular complications as the primary contributor to mortality, with coronary heart diseases accounting for 2,009 deaths. Neurodegenerative disorders represented the second largest category, as Alzheimer disease and other forms of dementia were linked to 1,652 deaths. Additionally, cerebrovascular diseases were cited in 1,171 deaths, alongside significant contributions from chronic kidney disease and various digestive cancers.
The study will operate at three Canadian sites and enroll about 80 healthy adults. Researchers will assess the vaccine’s safety, tolerability and ability to produce an immune response. The trial will not determine whether the vaccine prevents infection because Phase 1 studies focus on early safety data. The Coalition for Epidemic Preparedness Innovations has committed up to $50 million for preclinical work, the trial and production of additional research doses.